Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Hui, San-ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S812000
Reexamination Certificate
active
07943631
ABSTRACT:
The present invention relates a method of treating drug addiction in an individual by administering to the addicted individual a therapeutically effective amount of dextro-morphine capable of activating an opioid receptor. It is disclosed here that dextro-morphine is suitable for treating addiction to natural opiates, semi-synthetic opiates, fully synthetic opioids, and endogenous opioid peptides, as well as nicotine.
REFERENCES:
Horan B, Gardner EL, Dewey SL, Brodie JD, and Ashby CR, “The selective sigma(1) receptor agonist, 1-(3,4-dimethoxyphenethyl)-4-(phenylpropyl)piperazine (SA4503), blocks the acquisition of the conditioned place preference response to (−)-nicotine in rats,” European Journal of Pharmacology, Aug. 2001, 426(1-2), R1-R2.
Maurice T, Casalino M, Lacroix M, and Romieu P, “Involvement of the sigma 1 receptor in the motivational effects of ethanol in mice,” Pharmacoloogy Biochemistry and Behavior, Mar. 2003, 74(4), 869-876.
Romieu P, Phan VL, Martin-Fardon R, and Maurice T, “Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade,” Neuropsychopharmacology, Apr. 2002, 26(4), 444-455.
Stefanski R, Justinova Z, Hayashi T, Takebayashi M, Goldberg SR, and Su TP, “Sigma1 receptor upregulation after chronic methamphetamine self-administration in rats: a study with yoked controls,” Psychopharmacology, Aug. 2004, 175(1), 68-75.
Wu HE, Schwasinger ET, Terashvili M, and Tseng LF, “dextro-Morphine attenuates the morphine-produced conditioned place preference via the sigma(1) receptor activation in the rat,” European Journal of Pharmacology, May 2007, 562(3), 221-226 (Epub Feb. 8, 2007).
Monnet FP, Debonnel G, and de Montigny C, “In vivo electrophysiological evidence for a selective modulation of N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands,” Journal of Pharmacology and Experimental Therapeutics, Apr. 1992, 261(1), 123-130.
Balfour et al.,“The Putative Role of Extra-Synaptic Mesolimbic dopamine in the Neurobiology of Nicotine Dependence,” Behavioural Brain Research (2000) 113:73-83.
Bonci et al., “The Dopamine-containing Neuron: Maestro or Simple Musician in the Orchestra of Addiction?,” TRENDS in Pharmacological Sciences (Apr. 2003) 24(4):172-177.
Contet et al., “Mu Opioid Receptor: A Gateway to Drug Addiction,” Current Opinion in Neurobiology (2004) 14:370-378.
Dani et. al., “Synaptic Plasticity and Nicotine Addiction,” Neuron (2001) 31:349-352.
De Vries, Taco J. and Shippenberg, Toni S., “Neural Systems Underlying Opiate Addiction,” The Journal of Neurosciences (2002) 22(9):3321-3325.
Iijima et al., “Studies in the (+)-Morphinan Series. 4. A Markedly Improved Synthesis of (+)- Morphine,” J. Org. Chem. (1978) 43(7):1462-1463.
Jacquet et al., “Stereospecific and Nonstereospecific Effects of (+)-and (−)- Morphine: Evidence for a New Class of Receptors,” Science (1977) 198:842-845.
Joels, Marian, “Corticosteroid Effects in the Brain: U-shape it,” TRENDS in Pharmacological Sciences (2006) 27 (5):244-250.
McCracken et al., “Two Novel Sigma Receptor Ligands, BD1047 and LR172, Attenuate Cocaine-Induced Toxicity and Locomotor Activity,” European Journal of Pharamacology, (1999) 370:255-232.
Mei, J and Pasternak, G., “Sigma1 Receptor Modulation of Opioid Analgesia in the Mouse,” The Journal of Pharmacology and Experimental Therapeutics (2002) 300(4):1070-1074.
Monnet, Francois and Tangui, Maurice, “The Sigma1 Protein as a Target fot the Non-genomic Effects of Neuro (active)steroids: Molecular, Physiological, and Behavioral Aspects,” Journal of Pharmacological Sciences (2006) 100:93-118.
Mucha, Ronald and Herz, Albert, “Preference Conditioning Produced by Opioid Active and Inactive Isomers of Levorphanol and Morphine in Rat,” Life Science (1986) 38:241-249.
Olmstead, Mary and Burns, Lindsay, “Ultra-low-dose Naltrexone Suppresses Rewarding Effects of Opiates and Aversive Effects of Opiate Withdrawal in Rats,” Psychopharmacology (2005) 181:576-581.
Pilotte, Nancy S., “Neurochemistry of Cocaine Withdrawal,” Current Opinion in Neurology (1997) 10:534-538.
Romieu et al., “Sigma1 Receptor-Related Neuroactive Steroids Modulate Cocaine-Induced Reward,” The Journal of Neuroscience (2003) 23(9):3572-3576.
Shippenberg, Toni and Elmer, Gregory, “The Neurobiology of Opiate Reinforcement,” Critical Reviews in Neurobiology, (1998) 12(4):267-303.
Terashvili et al., “Differential Conditioned Place Preference Responses to Endomorphin-1 and endomorpin-2 Microinjected into the Posterior Nucleus Accumbens Shell and Ventral Tegmental Area in the Rat,” The Journal of Pharmacology and Experimental Therapeutics (2004) 309(2):816-824.
Terashvili et al., “(+)-Morphine and (−)-Morphine Stereoselectively Attenuate the (−)-morphine-produced Tail-flick Inhibition via the Naloxone-sensitive Sigma Receptor in the Ventral Periaqueductal Gray of the Rat,” European Journal of Pharmacology (2007) 571:1-7.
Terashvili et al., “(+)-Morphine attenuates the (−)-Morphine-produced Conditioned Place Preference and the Mu-opioid Receptor-mediated Dopamine Increase in the Posterior Nucleus Accumbens of the Rat,” European Journal of Pharmacology (2008) 587:147-154.
Tsao, Li-i and Su, Tsung-Ping, “Naloxone-Sensitive, Haloperidol-Sensitive, [3H] (+)SKF-10047-Binding Protein Partially Purified From Rate Liver and Rat Brain Membranes: and Opioid/Sigma Receptor,” Synapse (1997) 25:117-124.
Wu et al., “Opposite Conditioned Place Preference Response to Endomorphin-1 and Endomorphin-2 in the Mouse,” Neuroscience Letters (2004) 365:157-161.
Wu et al., “Stereoselective Action of dextro-Morphine over levo-Morphine on Glia in the Mouse Spinal Cord,” The Journal of Pharmacology and Experimental Therapeutics (2005) 314(3):1101-1108.
Hui San-ming
MCW Research Foundation, Inc.
Quarles & Brady LLP
Vinarov Sara D.
Zarek Paul
LandOfFree
Method of treating drug addiction using dextro-morphine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating drug addiction using dextro-morphine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating drug addiction using dextro-morphine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2697571